We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases / Novasep invests €6.1 million to upgrade its manufacturing facility for Active Pharmaceutical Ingredients at its Mourenx site

Novasep invests €6.1 million to upgrade its manufacturing facility for Active Pharmaceutical Ingredients at its Mourenx site

Novasep invests €6.1 million to upgrade its manufacturing facility for Active Pharmaceutical Ingredients at its Mourenx site
24 Jun 2021





• Novasep continues its investment strategy by upgrading its API manufacturing facility at its Mourenx site, increasing its flexibility and competitiveness
• A €6.1 million investment will be made over 3 years
• This investment has been selected by the French Government to be supported by ‘France Relance’, the post-Covid recovery plan
• 7 full-time jobs to be created

 

Lyon, France – June 24, 2021 - Novasep, a leading supplier of services and technologies for the life sciences industry, is pleased to announce a €6.1 million investment on its Mourenx site (Pyrénées-Atlantiques – France). This investment will modernize its API manufacturing facility, and reinforce its competitiveness in its markets, worldwide.

The modernization of this cGMP workshop includes the installation of new equipment and the revamping of clean rooms for API isolation. This project will enhance Novasep’s flexibility and develop a high-performance capacity for the custom manufacturing of innovative therapeutic molecules, in accordance with the highest quality and safety requirements and with improved environmental protection. To accompany this investment, Novasep also announces the creation of 7 full-time jobs on this site.

This project has been selected as part of the France Relance recovery plan initiated by the French government; Novasep will be supported within the framework of the "Investissements d'Avenir" (Investments for the future) program which rewards innovative and promising industrial investments, in order to allow France to increase its economic growth and employment potential.

This investment sends a strong signal to our customers and partners by increasing our market competitiveness. It further supports our strategy of reinforcing our high-quality offer for the commercial production of innovative therapies. I am proud of this investment which contributes to manufacturing jobs in France and allows us to further develop our activity in the Aquitaine region” says Dr. Michel Spagnol, Chairman and CEO of Novasep.

About Novasep
Novasep offers flexible contract development & manufacturing (CDMO) solutions for small molecules APIs & biopharmaceuticals to innovators. We propose a wide range of flexible cGMP manufacturing assets on multiple sites with an outstanding regulatory track record. We are a world leader in a number of specialized technologies including HPAPIs, ADCs, hazardous & cryogenic chemistry & industrial chromatography (batch and continuous).

Press contact
Thomas Goldberg
+33 4 37 28 20 57
Communication Project Manager
press@novasep.com

Novasep Icon PDF 2021 06_PR Musyc Project_EN

Novasep Icon PDF 2021 06_PR Musyc Project_FR

Novasep Icon PDF 2021 06_PR Musyc Project_DE

France Relance Logo


Back to full list of events

You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Your brochure is ready!

X

You can stay on this page and select more documents or you can directly download the brochure(s) you selected

Give us your feedback!